NMRA Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Cash Position: As of December 31, 2025, NMRA reported $182.5 million in cash, cash equivalents, and marketable securities, expected to fund operations into Q3 2027.
Net Loss: The total net loss for 2025 was comparable to 2024, indicating stable operating expenses.

2. Strategic Updates and Business Highlights

Pipeline Progress: NMRA made significant advancements in their clinical pipeline, particularly:
- NMRA-511: Positive results from a Phase Ib study for Alzheimer's disease agitation, showing a clinically meaningful effect size and favorable safety profile. Plans for a Phase II study in Q1 2027.
- Navacaprant: Fully enrolled Phase III studies (KOASTAL-2 and KOASTAL-3) for major depressive disorder, with data expected in Q2 2026.
- M4 PAM Franchise: NMRA-898 designated as the lead program for schizophrenia, showing promising early clinical results. NMRA-861 development paused but remains a viable option for future indications.
- NMRA-215: Positive data from a diet-induced obesity study, demonstrating class-leading weight loss potential. However, there were unexpected adverse findings in a rat toxicology study, prompting a for-cause audit.

3. Forward Guidance and Outlook

Upcoming Milestones: NMRA is positioned for multiple clinical data readouts in 2026, with a focus on advancing NMRA-511 and navacaprant.
Regulatory Strategy: For navacaprant, one positive study plus supportive evidence may suffice for a pre-NDA meeting with the FDA.
NMRA-215: Expected to enter the clinic in Q1 2027 after addressing toxicology study concerns.

4. Bad News, Challenges, or Points of Concern

Toxicology Findings: Unexpected adverse findings in a rat study for NMRA-215 have raised concerns. The company is conducting a repeat study and has opened an audit, which may delay the program.
Regulatory Uncertainty: While there is optimism regarding the potential for one positive study to support regulatory submissions, the outcome remains uncertain until data is available.
Market Competition: NMRA faces competitive pressures in the CNS therapeutic space, particularly with other companies developing similar mechanisms.

5. Notable Q&A Insights

Navacaprant Filing: Clarification that either KOASTAL-2 or KOASTAL-3 could serve as the positive study needed for regulatory submission, with supportive evidence potentially coming from the pooled analysis of post-protocol amendment patients.
NMRA-215 Toxicology Study: The findings were deemed procedure-related, and the company is confident in the repeat study's ability to clear the IND based on industry precedents.
M4 PAM Program Differentiation: NMRA-898 is positioned as a strong candidate in the schizophrenia space, with a favorable pharmacokinetic profile compared to competitors, and the potential for once-daily dosing is emphasized.

Overall, NMRA has made substantial progress in its clinical pipeline while facing challenges related to toxicology findings and the competitive landscape. The company remains optimistic about upcoming milestones and regulatory pathways.

NMRA — Neumora Therapeutics, Inc. Common Stock